—
C+
C+ The full Closelooknet — membership. Open the C+ overview

TG Therapeutics Inc (TGTX) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for TGTX, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sector × region Health care in US: −2.1% week · −2.2% month · +3.3% quarter · +16.4% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.73 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How TGTX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.73 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), TG Therapeutics Inc moved 0.73% on average · correlation 0.15 · higher than 72% of US names
  • Beta, last 3 months 0.57 about the same as over the year
  • On the 10 worst bond days −1.54% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +2.71% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against TGTX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — TG Therapeutics Inc

TGTX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
TG Therapeutics is a commercial-stage biopharmaceutical company that develops treatments for diseases driven by B-cells, a type of immune cell. Its approved product, an antibody therapy for relapsing forms of multiple sclerosis, is sold in the United States and other markets. The pipeline behind it includes further antibody and kinase-inhibitor candidates aimed at the same B-cell pathways. The company is based in Morrisville, North Carolina.
Where it sits in the stack
TG Therapeutics has no seat in our index and no place in the AI build-out layers we track; it sits in the wider universe under Healthcare, in the biotechnology industry, and stops there.
Who it is priced against
The diary has no defined peer group for this name; the market often compares it with larger multiple-sclerosis therapies from Novartis and Roche, which target the same B-cell pathway.
Why Closelooknet tracks it
It is not part of our index and carries no quote history in the diary, but it does carry a Closelooknet score, with momentum standing out as the module the score currently rests on.
What the diary watches
Whether sales of the approved multiple-sclerosis therapy keep expanding and how the pipeline candidates progress, since that would shift the read beyond the current price momentum.

TG Therapeutics Inc (TGTX) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 54/100 composite (momentum 69, quality 68, valuation 28) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return no distribution in twelve months · buybacks 91 m USD in FY2025

Dividends and capital return

What TGTX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 91 m USD 1.1% of today's market value
  • Share count +0.7% in FY2025 65 m USD of stock-based compensation in the year
  • Capital returned 91 m USD in a year of negative free cash flow dividends and buybacks together

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is TG Therapeutics Inc (TGTX)?

TG Therapeutics Inc trades as TGTX on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is TGTX in a Closelooknet index?

Not currently — TG Therapeutics Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

What is TG Therapeutics Inc's Closelooknet composite score?

54 out of 100, with momentum 69, quality 68 and valuation 28 sub-scores, as of 2026-10-07. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does TGTX trade against its moving averages?

Pullback inside an uptrend stack: Trades -2.6% vs the 50-day and +25.6% vs the 200-day average, 12% below the 52-week high and +95% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does TG Therapeutics Inc compare with its peers?

Against its peer group (Biotechnology · US), TG Therapeutics Inc (TGTX) sits 12.0% below its 52-week high, 2.6% below its 50-day average; BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Caris Life Sciences, Inc. Common Stock (CAI) is 18.4% below. Put any of them next to TGTX in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does TG Therapeutics Inc trade when bond yields rise?

Over the past year TG Therapeutics Inc had a beta of 0.73 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 72% of US names. On the 10 sessions in which long bonds fell most it moved −1.54% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does TG Therapeutics Inc do?

TG Therapeutics is a commercial-stage biopharmaceutical company that develops treatments for diseases driven by B-cells, a type of immune cell. Its approved product, an antibody therapy for relapsing forms of multiple sclerosis, is sold in the United States and other markets. The pipeline behind it includes further antibody and kinase-inhibitor candidates aimed at the same B-cell pathways. The diary has no defined peer group for this name; the market often compares it with larger multiple-sclerosis therapies from Novartis and Roche, which target the same B-cell pathway.

Where does TG Therapeutics Inc sit in the AI build-out?

TG Therapeutics has no seat in our index and no place in the AI build-out layers we track; it sits in the wider universe under Healthcare, in the biotechnology industry, and stops there. It is not part of our index and carries no quote history in the diary, but it does carry a Closelooknet score, with momentum standing out as the module the score currently rests on.

Does TG Therapeutics Inc pay a dividend?

No cash distribution shows in TG Therapeutics Inc’s price series over the last three years. In fiscal 2025 the company bought back 91 m USD of its own shares. The share count rose 0.7% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for TGTX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.